Database→AOD-9604

Tier 3–4Weight LossMetabolicPREMIUM

AOD-9604

AOD-9604 (Advanced Obesity Drug / hGH Fragment 176-191 / Tyr-hGH177-191)

Not FDA-approved. Cannot be legally compounded in the United States. PCAC voted against inclusion on 503A bulks list, December 4, 2024. GRAS status held for food and dietary supplement oral use only, not injectable. Not approved in Australia (TGA), EU (EMA), or any major jurisdiction. Sold as research chemical.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use

Profile Overview

AOD-9604 is a synthetic 16-amino acid fragment of the C-terminus of human growth hormone (hGH residues 176 to 191), developed at Monash University in the 1990s as a selective anti-obesity drug. Six human clinical trials involving approximately 900 participants established a clean safety profile. A Phase IIa trial (n=300, 12 weeks) showed 2.6 to 2.8 kg additional weight loss at 1 mg/day versus 0.8 kg placebo. The pivotal Phase IIb OPTIONS trial (n=536, 24 weeks) failed to replicate this finding at any dose. Development was terminated in 2007. Cannot be legally compounded in the United States as of March 2026.

🔒

Full Profile: Premium Members Only

The complete AOD-9604 profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use